CBARP

Summary

CBARP (CACN subunit beta associated regulatory protein, HGNC:28617) is a protein-coding gene on chromosome 19p13.3, encoding Voltage-dependent calcium channel beta subunit-associated regulatory protein (Q8N350). Negatively regulates voltage-gated calcium channels by preventing the interaction between their alpha and beta subunits.

Predicted to enable transmembrane transporter binding activity. Predicted to be involved in negative regulation of calcium ion-dependent exocytosis and negative regulation of voltage-gated calcium channel activity. Predicted to be located in growth cone and secretory granule. Predicted to be active in plasma membrane.

Source: NCBI Gene 255057 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 43 total — 1 pathogenic
• MANE Select transcript: NM_001393918

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:28617
Approved symbol	CBARP
Name	CACN subunit beta associated regulatory protein
Location	19p13.3
Locus type	gene with protein product
Status	Approved
Aliases	MGC40084, DOS, BARP
Ensembl gene	ENSG00000099625
Ensembl biotype	protein_coding
Entrez	255057

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 7 protein_coding, 2 retained_intron, 2 nonsense_mediated_decay

ENST00000215376, ENST00000382477, ENST00000589260, ENST00000590083, ENST00000591127, ENST00000648750, ENST00000650044, ENST00000917007, ENST00000942888, ENST00000942889, ENST00000942890

RefSeq mRNA: 2 — MANE Select: NM_001393918 NM_001393918, NM_152769

CCDS: CCDS12057, CCDS92477

Canonical transcript exons

ENST00000650044 — 10 exons

Exon	Start	End
ENSE00000651449	1234191	1234331
ENSE00000795123	1234571	1234742
ENSE00000795124	1235001	1235145
ENSE00000795125	1235779	1235918
ENSE00003575046	1233426	1233636
ENSE00003588315	1231101	1231275
ENSE00003712864	1235501	1235565
ENSE00003832605	1228287	1230142
ENSE00003839343	1235996	1236121
ENSE00003930470	1237756	1238005

Expression profiles

Bgee: expression breadth ubiquitous, 182 present calls, max score 88.04.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 6.6995 / max 138.6809, expressed in 1439 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
178000	3.7499	1292
177998	1.6465	492
177999	1.2019	576
177995	0.1012	55

Top tissues by expression

279 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
adenohypophysis	UBERON:0002196	88.04	gold quality
nucleus accumbens	UBERON:0001882	86.51	gold quality
pituitary gland	UBERON:0000007	86.45	gold quality
right frontal lobe	UBERON:0002810	85.86	gold quality
prefrontal cortex	UBERON:0000451	84.97	gold quality
caudate nucleus	UBERON:0001873	84.77	gold quality
cingulate cortex	UBERON:0003027	83.51	gold quality
putamen	UBERON:0001874	83.40	gold quality
anterior cingulate cortex	UBERON:0009835	83.36	gold quality
buccal mucosa cell	CL:0002336	83.32	silver quality
cortical plate	UBERON:0005343	83.19	gold quality
neocortex	UBERON:0001950	82.22	gold quality
frontal cortex	UBERON:0001870	82.10	gold quality
frontal lobe	UBERON:0016525	82.07	gold quality
ganglionic eminence	UBERON:0004023	82.03	gold quality
amygdala	UBERON:0001876	81.07	gold quality
sperm	CL:0000019	80.94	silver quality
telencephalon	UBERON:0001893	80.87	gold quality
forebrain	UBERON:0001890	80.79	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	80.53	gold quality
cerebral cortex	UBERON:0000956	80.47	gold quality
ventricular zone	UBERON:0003053	79.72	gold quality
Ammon’s horn	UBERON:0001954	79.53	gold quality
brain	UBERON:0000955	79.15	gold quality
temporal lobe	UBERON:0001871	78.96	gold quality
central nervous system	UBERON:0001017	78.67	gold quality
Brodmann (1909) area 9	UBERON:0013540	78.63	gold quality
stromal cell of endometrium	CL:0002255	78.59	gold quality
male germ cell	CL:0000015	78.37	silver quality
primary visual cortex	UBERON:0002436	78.33	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	1.22

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

20 targeting CBARP, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4441	99.49	66.56	3216
HSA-MIR-6722-3P	99.45	67.62	1919
HSA-MIR-19A-5P	99.36	66.93	1675
HSA-MIR-19B-1-5P	99.36	67.07	1669
HSA-MIR-19B-2-5P	99.36	67.07	1669
HSA-MIR-1909-3P	99.03	66.56	1662
HSA-MIR-6827-5P	98.46	64.88	1256
HSA-MIR-4660	97.79	67.44	1328
HSA-MIR-3189-5P	97.55	66.71	655
HSA-MIR-6787-5P	97.54	63.85	457
HSA-MIR-1913	97.07	66.20	1417
HSA-MIR-1288-3P	96.86	66.95	536
HSA-MIR-1287-5P	96.80	65.30	743
HSA-MIR-4515	95.70	65.73	716
HSA-MIR-10396B-5P	94.99	63.57	358
HSA-MIR-1908-5P	94.99	63.41	352
HSA-MIR-663A	94.99	63.54	378
HSA-MIR-6727-5P	92.41	61.98	83
HSA-MIR-4258	90.68	62.19	164
HSA-MIR-4508	90.37	59.62	240

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	cbarpb	ENSDARG00000071325
mus_musculus	Cbarp	ENSMUSG00000035640
rattus_norvegicus	Cbarp	ENSRNOG00000024349

Protein

Protein identifiers

Voltage-dependent calcium channel beta subunit-associated regulatory protein — Q8N350 (reviewed: Q8N350)

All UniProt accessions (4): Q8N350, A0A140LJL2, A0A3B3IRU5, K7ELJ5

UniProt curated annotations — full annotation on UniProt →

Function. Negatively regulates voltage-gated calcium channels by preventing the interaction between their alpha and beta subunits. Thereby, negatively regulates calcium channels activity at the plasma membrane and indirectly inhibits calcium-regulated exocytosis.

Subunit / interactions. Interacts with voltage-dependent calcium channels CACNB1, CACNB2, CACNB3 and CACNB4 beta subunits; prevents their interaction with the CACNA1C alpha subunit thereby negatively regulating the activity of the corresponding calcium channels.

Subcellular location. Cytoplasmic vesicle. Secretory vesicle. Synaptic vesicle membrane. Cell membrane. Cell projection. Growth cone.

Isoforms (2)

UniProt ID	Names	Canonical?
Q8N350-3	1	yes
Q8N350-4	2

RefSeq proteins (2): NP_001380847, NP_689982 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR037658	CBARP	Family

UniProt features (32 total): compositionally biased region 9, modified residue 8, region of interest 6, topological domain 2, splice variant 2, sequence conflict 2, chain 1, transmembrane region 1, glycosylation site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8N350-F1	52.23	0.05

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (8): 299, 304, 507, 528, 621, 698, 699, 703

Glycosylation sites (1): 29

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 100 (showing top): MORF_RAGE, GOBP_NEGATIVE_REGULATION_OF_TRANSMEMBRANE_TRANSPORT, YAGI_AML_WITH_INV_16_TRANSLOCATION, GOBP_NEGATIVE_REGULATION_OF_TRANSPORTER_ACTIVITY, GOCC_SECRETORY_GRANULE, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, GOBP_REGULATION_OF_EXOCYTOSIS, GOBP_NEGATIVE_REGULATION_OF_CALCIUM_ION_DEPENDENT_EXOCYTOSIS, GOBP_REGULATION_OF_VOLTAGE_GATED_CALCIUM_CHANNEL_ACTIVITY, GOBP_VESICLE_MEDIATED_TRANSPORT, GOBP_NEGATIVE_REGULATION_OF_EXOCYTOSIS, GOBP_NEGATIVE_REGULATION_OF_REGULATED_SECRETORY_PATHWAY, GOBP_MONOATOMIC_CATION_TRANSPORT, GOBP_REGULATION_OF_VESICLE_MEDIATED_TRANSPORT, GOBP_EXOCYTOSIS

GO Biological Process (3): negative regulation of calcium ion-dependent exocytosis (GO:0045955), negative regulation of voltage-gated calcium channel activity (GO:1901386), negative regulation of calcium ion transmembrane transport (GO:1903170)

GO Molecular Function (2): transmembrane transporter binding (GO:0044325), protein binding (GO:0005515)

GO Cellular Component (8): plasma membrane (GO:0005886), secretory granule (GO:0030141), growth cone (GO:0030426), synaptic vesicle membrane (GO:0030672), membrane (GO:0016020), cytoplasmic vesicle (GO:0031410), cell projection (GO:0042995), synapse (GO:0045202)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
calcium-ion regulated exocytosis	1
regulation of calcium ion-dependent exocytosis	1
negative regulation of regulated secretory pathway	1
voltage-gated calcium channel activity	1
negative regulation of calcium ion transmembrane transporter activity	1
regulation of voltage-gated calcium channel activity	1
negative regulation of calcium ion transport	1
calcium ion transmembrane transport	1
regulation of calcium ion transmembrane transport	1
negative regulation of cation transmembrane transport	1
protein binding	1
binding	1
membrane	1
cell periphery	1
endomembrane system	1
secretory vesicle	1
site of polarized growth	1
distal axon	1
synaptic vesicle	1
exocytic vesicle membrane	1
cytoplasm	1
intracellular vesicle	1
cell junction	1

Protein interactions and networks

STRING

374 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CBARP	FAM174C	Q9BVV8	544
CBARP	CLRN3	Q8NCR9	491
CBARP	FSIP2	Q5CZC0	456
CBARP	CRABP2	P29373	419
CBARP	GHITM	Q9H3K2	415
CBARP	SBNO2	Q9Y2G9	396
CBARP	C19orf25	Q9UFG5	395
CBARP	R3HDM4	Q96D70	393
CBARP	RMDN2	Q96LZ7	379
CBARP	ANKMY1	Q9P2S6	370
CBARP	QRICH2	Q9H0J4	368
CBARP	MAF1	Q9H063	367
CBARP	H7C0V5	H7C0V5	349
CBARP	CIMAP1D	Q3SX64	316
CBARP	NR1I3	Q14994	316

IntAct

51 interactions, top by confidence:

A	B	Type	Score
PPP1CC	CCDC85C	psi-mi:“MI:0914”(association)	0.740
CACNB1	CACNB3	psi-mi:“MI:0914”(association)	0.640
YWHAH	PLEKHG3	psi-mi:“MI:0914”(association)	0.610
STARD3	CBARP	psi-mi:“MI:0915”(physical association)	0.590
YWHAQ	IGLC7	psi-mi:“MI:0914”(association)	0.530
CACNB3	CACNB4	psi-mi:“MI:0914”(association)	0.530
CACNB3	CACNB2	psi-mi:“MI:0914”(association)	0.530
YWHAB	PLEKHG3	psi-mi:“MI:0914”(association)	0.480
YWHAQ	PLEKHG3	psi-mi:“MI:0914”(association)	0.480
CBARP	PKM	psi-mi:“MI:0217”(phosphorylation reaction)	0.440
PPP1CC	CCDC85C	psi-mi:“MI:0914”(association)	0.350
FADS3	DHX16	psi-mi:“MI:0914”(association)	0.350
CACNB3	PLCG1	psi-mi:“MI:0914”(association)	0.350
TMC6	PXK	psi-mi:“MI:0914”(association)	0.350
YWHAB	PLEKHG3	psi-mi:“MI:0914”(association)	0.350
YWHAG	C1orf226	psi-mi:“MI:0914”(association)	0.350
YWHAZ	SPEG	psi-mi:“MI:0914”(association)	0.350
CACNA1C	IGLL5	psi-mi:“MI:0914”(association)	0.350
HCN1	POTEF	psi-mi:“MI:0914”(association)	0.350
YWHAB	FOXO6	psi-mi:“MI:0914”(association)	0.350
YWHAG	FOXO6	psi-mi:“MI:0914”(association)	0.350
YWHAQ	FOXO6	psi-mi:“MI:0914”(association)	0.350
YWHAH	FOXO6	psi-mi:“MI:0914”(association)	0.350
YWHAZ	HECTD4	psi-mi:“MI:0914”(association)	0.350
CBARP	BIN1	psi-mi:“MI:0914”(association)	0.350
FADS3	PEX7	psi-mi:“MI:0914”(association)	0.350
CEP55	SRC	psi-mi:“MI:0914”(association)	0.350

BioGRID (98): C19orf26 (Affinity Capture-MS), C19orf26 (Proximity Label-MS), C19orf26 (Proximity Label-MS), C19orf26 (Affinity Capture-MS), C19orf26 (Affinity Capture-MS), C19orf26 (Affinity Capture-MS), C19orf26 (Affinity Capture-MS), C19orf26 (Affinity Capture-MS), C19orf26 (Affinity Capture-MS), C19orf26 (Proximity Label-MS), C19orf26 (Proximity Label-MS), C19orf26 (Proximity Label-MS), C19orf26 (Two-hybrid), C19orf26 (Two-hybrid), C19orf26 (Two-hybrid)

ESM2 similar proteins: A2A699, A2A9T0, A2AEV7, A2AJA9, A6NKL6, A6NL88, A7MCY6, A8MVW0, C9J069, E9PZZ1, J3QNX5, O14492, O14511, O15169, O35615, O43541, O94983, P0C7U0, Q02779, Q03484, Q148V8, Q3SX20, Q5BJT1, Q5JTD0, Q5JU85, Q63HR2, Q66H43, Q66L44, Q69YU3, Q6DG50, Q6PDH0, Q6R6L0, Q6ZRV2, Q75VX8, Q7TN12, Q80VC9, Q80Y50, Q86UU1, Q8C3Q5, Q8C8T7

Diamond homologs: Q66L44, Q8N350

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 51 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Activation of BAD and translocation to mitochondria	7	144.0×	3e-12
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex	7	127.1×	4e-12
SARS-CoV-1 targets host intracellular signalling and regulatory pathways	7	127.1×	4e-12
Activation of BH3-only proteins	7	93.9×	4e-11
RHO GTPases activate PKNs	7	60.0×	9e-10
Intrinsic Pathway for Apoptosis	7	55.4×	1e-09
FOXO-mediated transcription	5	45.4×	1e-06
NCAM signaling for neurite out-growth	6	44.1×	1e-07

GO biological processes:

GO term	Partners	Fold	FDR
regulation of heart rate by cardiac conduction	7	55.8×	1e-08
protein targeting	5	39.0×	4e-05
intracellular protein localization	7	15.6×	4e-05

Disease & clinical

Clinical variants and AI predictions

ClinVar

43 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	33
Likely benign	5
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
60067	GRCh38/hg38 19p13.3(chr19:1156372-1228333)x1	Pathogenic

SpliceAI

1691 predictions. Top by Δscore:

Variant	Effect	Δscore
19:1231276:CTGC:C	acceptor_loss	1.0000
19:1234201:T:TA	donor_gain	1.0000
19:1234202:C:A	donor_gain	1.0000
19:1234566:CTCA:C	donor_loss	1.0000
19:1234567:TCACC:T	donor_loss	1.0000
19:1234568:CACC:C	donor_loss	1.0000
19:1234741:ACCTG:A	acceptor_loss	1.0000
19:1234743:CTG:C	acceptor_loss	1.0000
19:1234744:T:G	acceptor_loss	1.0000
19:1234995:GCTTA:G	donor_loss	1.0000
19:1234998:TACC:T	donor_loss	1.0000
19:1234999:A:AC	donor_gain	1.0000
19:1235000:C:CA	donor_gain	1.0000
19:1235915:CTGC:C	acceptor_gain	1.0000
19:1235916:TGC:T	acceptor_gain	1.0000
19:1235917:GC:G	acceptor_gain	1.0000
19:1235918:CC:C	acceptor_gain	1.0000
19:1235919:C:CC	acceptor_gain	1.0000
19:1235923:G:T	acceptor_gain	1.0000
19:1236005:T:TA	donor_gain	1.0000
19:1236122:CT:C	acceptor_loss	1.0000
19:1231180:A:AC	donor_gain	0.9900
19:1231181:C:CC	donor_gain	0.9900
19:1231276:C:CC	acceptor_gain	0.9900
19:1233035:C:T	acceptor_gain	0.9900
19:1233421:CTCA:C	donor_loss	0.9900
19:1233422:TCA:T	donor_loss	0.9900
19:1233423:CACCT:C	donor_loss	0.9900
19:1233425:C:CG	donor_loss	0.9900
19:1233425:CCT:C	donor_gain	0.9900

AlphaMissense

4516 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:1234710:A:G	L163P	0.999
19:1234718:G:C	F160L	0.999
19:1234718:G:T	F160L	0.999
19:1234719:A:C	F160C	0.999
19:1234719:A:G	F160S	0.999
19:1234720:A:G	F160L	0.999
19:1234706:C:A	K164N	0.998
19:1234706:C:G	K164N	0.998
19:1234734:A:G	L155P	0.998
19:1229638:G:C	F553L	0.997
19:1229638:G:T	F553L	0.997
19:1229640:A:G	F553L	0.997
19:1229788:A:C	S503R	0.997
19:1229788:A:T	S503R	0.997
19:1229790:T:G	S503R	0.997
19:1229792:T:A	D502V	0.997
19:1229794:C:A	M501I	0.997
19:1229794:C:G	M501I	0.997
19:1229794:C:T	M501I	0.997
19:1229985:A:G	W438R	0.997
19:1229985:A:T	W438R	0.997
19:1233439:A:C	S322R	0.997
19:1233439:A:T	S322R	0.997
19:1233441:T:G	S322R	0.997
19:1234722:T:C	D159G	0.997
19:1229639:A:G	F553S	0.996
19:1229776:G:C	S507R	0.996
19:1229776:G:T	S507R	0.996
19:1229778:T:G	S507R	0.996
19:1229784:A:G	Y505H	0.996

dbSNP variants (sampled 300 via entrez): RS1000315192 (19:1239080 A>C), RS1000358125 (19:1231757 C>T), RS1000418666 (19:1233882 G>A,C), RS1000420642 (19:1235322 C>A,G,T), RS1000505074 (19:1237165 G>A,C), RS1000533316 (19:1238151 G>A,C), RS1000599570 (19:1236675 C>T), RS1000758309 (19:1234522 G>A), RS1001025438 (19:1232992 C>A,T), RS1001561230 (19:1232791 C>G,T), RS1001634165 (19:1230833 C>G,T), RS1001742962 (19:1228067 T>C), RS1001807842 (19:1233179 G>A,C), RS1001854927 (19:1230164 C>CA), RS1001923681 (19:1237634 C>A,T)

Disease associations

OMIM: gene `` | disease phenotypes: MIM:175200

GenCC curated gene-disease

Mondo (1): Peutz-Jeghers syndrome (MONDO:0008280)

Orphanet (1): Peutz-Jeghers syndrome (Orphanet:2869)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D010580	Peutz-Jeghers Syndrome	C04.700.633; C06.405.469.578.750; C16.320.700.667; C17.800.621.430.530.550.625

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs2301759	CBARP		0.00	0

CTD chemical–gene interactions

30 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Air Pollutants	increases abundance, increases expression	2
Tobacco Smoke Pollution	decreases methylation, increases expression	2
Particulate Matter	increases abundance, increases expression	2
FR900359	increases phosphorylation	1
dicrotophos	increases expression	1
methyleugenol	decreases expression	1
bisphenol A	affects cotreatment, increases expression	1
beta-lapachone	increases expression	1
sodium arsenite	increases expression	1
perfluorooctanoic acid	increases expression	1
coumarin	decreases phosphorylation	1
abrine	increases expression	1
licochalcone B	increases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Sunitinib	increases expression	1
Allergens	increases expression	1
Benzo(a)pyrene	increases methylation	1
Cadmium	decreases expression, increases abundance	1
Caffeine	affects phosphorylation	1
Cisplatin	decreases expression	1
Dexamethasone	affects cotreatment, increases expression	1
Estradiol	increases expression	1
Indomethacin	affects cotreatment, increases expression	1
Plant Extracts	affects cotreatment, decreases expression	1
Urethane	increases expression	1
Valproic Acid	increases methylation	1
1-Methyl-3-isobutylxanthine	affects cotreatment, increases expression	1
Cyclosporine	decreases methylation	1
Cadmium Chloride	decreases expression, increases abundance	1
Okadaic Acid	increases expression	1

Clinical trials (associated diseases)

16 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT03781050	PHASE4	UNKNOWN	Efficacy of Rapamycin (Sirolimus) in the Treatment of Peutz-Jeghers Syndrome
NCT06001476	PHASE4	UNKNOWN	Cold Snare Polypectomy for Small Bowel Polyps in Patients With Peutz-Jeghers Syndrome
NCT02000089	PHASE3	RECRUITING	The Cancer of the Pancreas Screening-5 CAPS5)Study
NCT00811590	PHASE2	TERMINATED	Pilot Study of mTOR Inhibitor Therapy in Peutz-Jeghers Syndrome
NCT01178151	PHASE2	WITHDRAWN	Study of Everolimus in the Treatment of Advanced Malignancies in Patients With Peutz-Jeghers Syndrome
NCT00001452	Not specified	COMPLETED	Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex
NCT00438906	Not specified	COMPLETED	Cancer of the Pancreas Screening Study (CAPS 3)
NCT00633607	Not specified	COMPLETED	Hereditary Colorectal and Associated Tumor Registry Study
NCT02206360	Not specified	ACTIVE_NOT_RECRUITING	Pancreatic Cancer Early Detection Program
NCT03050268	Not specified	RECRUITING	Familial Investigations of Childhood Cancer Predisposition
NCT03806075	Not specified	UNKNOWN	Study of Accurate Diagnosis and Treatment of Peutz-Jeghers Syndrome
NCT04095195	Not specified	RECRUITING	Registry of Subjects at Risk of Pancreatic Cancer
NCT05692596	Not specified	ACTIVE_NOT_RECRUITING	The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics
NCT06163365	Not specified	UNKNOWN	Inherited Cancer Early Diagnosis (ICED) Study
NCT06242457	Not specified	COMPLETED	Poorly Differentiated Adenocarcinoma of the Jejunum in a Patient With Peutz-Jeghers Syndrome: A Case Report
NCT06722534	Not specified	RECRUITING	Celecoxib for Prevention of Progression in Peutz-Jeghers Syndrome